Ocular Therapeutix Inc

NASDAQ:OCUL  
5.51
-0.14 (-2.48%)
Products, Regulatory

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease

Published: 12/06/2021 13:01 GMT
Ocular Therapeutix Inc (OCUL) - Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of Otx-ded for the Short-term Treatment of Dry Eye Disease.
Ocular - Study Shows Significant Improvement for Primary Endpoint of Bulbar Conjunctival Hyperemia for Otx-ded 0.2 Mg and 0.3 Mg Formulations.
Ocular Therapeutix Inc - Both Formulations Were Generally Well Tolerated With Favorable Safety Profiles.